The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre
- PMID: 20883483
- DOI: 10.1111/j.1464-410X.2010.09697.x
The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre
Erratum in
-
Corrigendum.BJU Int. 2016 Apr;117(4):E8. doi: 10.1111/bju.13432. BJU Int. 2016. PMID: 26969034 No abstract available.
Abstract
Study Type--Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Bladder pain syndrome (BPS) is a chronic debilitating disease. A recently done survey estimates the prevalence of the BPS symptoms among adult females in the U.S. to be 7%. Conservative management is the first line of therapy but at least 10% of the patients show poor response. Sacral neuromodulation is a minimal invasive technique with good long-term outcomes in these patients. It should be considered before any invasive surgical intervention is planned. However, the revision rate is high and patients need lifelong follow-up.
Objective: • To evaluate the long-term success and tolerability of sacral neuromodulation (SNM) in the control of the symptoms of bladder pain syndrome (BPS).
Methods: • This was a retrospective study of all patients with BPS who underwent peripheral nerve evaluation and then SNM in our department of urology by a single surgeon from 1994 till 2008. The global response assessment scale was used to evaluate the outcome of the SNM.
Results: • A total of 78 patients fulfilled the International Consultation on Incontinence clinical criteria for BPS and showed cystoscopic evidence of glomerulation or ulcer as recommended by the European Society for the Study of Interstitial Cystitis/Painful Bladder Syndrome. All patients failed conservative management before considering SNM. • Permanent SNM implant was performed in patients who showed at least 50% improvement in their symptoms with a temporary peripheral nerve evaluation test. Median follow up was 61.5 months (SD ± 27.7). Good long-term success of the SNM was seen in 72% of the patients. • Presence of urgency was a positive predictor of the long-term success of the implant. The explantation rate was 28%. The commonest reason for explantation was poor outcome (54% of the failed patients). The revision rate was 50%. • The most common indication for revision was lack of stimulation sensation and worsening of symptoms. The average durability of the pulse generator battery was 93 months.
Conclusion: • SNM is an effective treatment to control the symptoms of BPS. It should be considered before any major invasive surgical intervention if conservative measures have failed. It is a minimally invasive, safe procedure with good long-term outcome. However, the revision rate is high and patients require lifelong follow-up.
Similar articles
-
Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up.Neurourol Urodyn. 2011 Sep;30(7):1271-5. doi: 10.1002/nau.21037. Epub 2011 May 6. Neurourol Urodyn. 2011. PMID: 21557299
-
Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction.BJU Int. 2014 May;113(5):789-94. doi: 10.1111/bju.12571. BJU Int. 2014. PMID: 24238278
-
Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures.J Urol. 2010 Jan;183(1):173-6. doi: 10.1016/j.juro.2009.08.142. J Urol. 2010. PMID: 19913835
-
Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.Int Urogynecol J. 2018 Aug;29(8):1081-1091. doi: 10.1007/s00192-017-3546-6. Epub 2018 Jan 4. Int Urogynecol J. 2018. PMID: 29302716 Review.
-
The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol.Neurourol Urodyn. 2018 Jun;37(S4):S99-S107. doi: 10.1002/nau.23493. Epub 2018 Jan 24. Neurourol Urodyn. 2018. PMID: 29363792 Review.
Cited by
-
Neuromodulation for Management of Chronic Pelvic Pain: A Comprehensive Review.Pain Ther. 2022 Dec;11(4):1137-1177. doi: 10.1007/s40122-022-00430-9. Epub 2022 Sep 15. Pain Ther. 2022. PMID: 36109459 Free PMC article. Review.
-
From bladder to systemic syndrome: concept and treatment evolution of interstitial cystitis.Int J Womens Health. 2015 Jul 23;7:735-44. doi: 10.2147/IJWH.S60798. eCollection 2015. Int J Womens Health. 2015. PMID: 26229509 Free PMC article. Review.
-
Efficacy of sacral neuromodulation in treating chronic pain related to painful bladder syndrome/interstitial cystitis in adults.J Anaesthesiol Clin Pharmacol. 2012 Oct;28(4):428-35. doi: 10.4103/0970-9185.101890. J Anaesthesiol Clin Pharmacol. 2012. PMID: 23225919 Free PMC article.
-
First evidence of neosaxitoxin as a long-acting pain blocker in bladder pain syndrome.Int Urogynecol J. 2015 Jun;26(6):853-8. doi: 10.1007/s00192-014-2608-2. Epub 2015 Jan 9. Int Urogynecol J. 2015. PMID: 25571865
-
The history of sacral neuromodulation in Canada.Can Urol Assoc J. 2020 Apr;14(4):87-90. doi: 10.5489/cuaj.6499. Epub 2020 Apr 1. Can Urol Assoc J. 2020. PMID: 32254010 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical